Compare AGPU & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGPU | PMVP |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 71.1M |
| IPO Year | 2008 | 2020 |
| Metric | AGPU | PMVP |
|---|---|---|
| Price | $11.52 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.20 |
| AVG Volume (30 Days) | 299.0K | ★ 515.8K |
| Earning Date | 11-13-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $125,284.00 | N/A |
| Revenue This Year | $48,110.47 | N/A |
| Revenue Next Year | $614.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $1.02 |
| 52 Week High | $13.49 | $1.88 |
| Indicator | AGPU | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 53.34 | 68.53 |
| Support Level | $7.00 | $1.05 |
| Resistance Level | $13.48 | $1.88 |
| Average True Range (ATR) | 0.98 | 0.11 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 33.56 | 89.89 |
Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, the company aims to provide access to bare-metal GPUs at scale for both emerging and established organizations.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.